BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sieczkowska-Golub J, Jarzebicka D, Oracz G, Kierkus J. Biosimilars in paediatric inflammatory bowel disease. World J Gastroenterol 2018; 24(35): 4021-4027 [PMID: 30254406 DOI: 10.3748/wjg.v24.i35.4021]
URL: https://www.wjgnet.com/1007-9327/full/v24/i35/4021.htm
Number Citing Articles
1
Iga Pawłowska, Leszek Pawłowski, Natalia Krzyżaniak, Ivan Kocić. Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General HospitalsBioDrugs 2019; 33(2): 183 doi: 10.1007/s40259-019-00341-w
2
Emanuil Yordanov, Iva Parvova, Emil Hristov, Valentina Petkova. Evaluation of the drug utilization of biosimilar medicinal products containing monoclonal antibodies: A systematic reviewJournal of Generic Medicines: The Business Journal for the Generic Medicines Sector 2022; 18(3): 145 doi: 10.1177/17411343221076371
3
Stefka Stoyanova, Emanuil Yordanov, Emil Hristov, Iva Parvova, Hristo Tzachev, Valentina Petkova. Availability, affordability and drug utilization of biosimilar medicinal products, containing monoclonal antibodies in BulgariaJournal of Generic Medicines: The Business Journal for the Generic Medicines Sector 2022; 18(1): 42 doi: 10.1177/17411343211017627
4
Lin-Chau Chang. The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyondJournal of Food and Drug Analysis 2019; 27(3): 671 doi: 10.1016/j.jfda.2019.03.003
5
Marleena Repo, Johanna Pessi, Eelis Wirtanen, Pauliina Hiltunen, Heini Huhtala, Laura Kivelä, Kalle Kurppa. Frequency and clinical significance of histologic upper gastrointestinal tract findings in children with inflammatory bowel diseaseScandinavian Journal of Gastroenterology 2022; 57(9): 1046 doi: 10.1080/00365521.2022.2057197